Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic determinants of therapy response in ETV6::RUNX1 leukemia.

Leukemia - 1 Sept 2025

Oksa Laura, Moisio Sanni, Maqbool Khurram, Kramer Roger, Nikkilä Atte, Jayasingha Buddika, Mäkinen Artturi, Foroughi-Asl Hassan, Rounioja Samuli, Suhonen Janne, Krali Olga, Voutilainen Miikka, Lahnalampi Mari, Vepsäläinen Kaisa, Huang Sui, Duque-Afonso Jesus, Hauer Julia, Nordlund Jessica, Wirta Valtteri, Lohi Olli, Heinäniemi Merja

Abstract excerpt

ETV6::RUNX1 leukemia is the second most common subtype of childhood B cell acute lymphoblastic leukemia (B-ALL). Although it generally has a low relapse risk, a significant proportion of B-ALL relapses occur within this subtype due to its relatively high incidence. Measurable residual disease at the end of induction therapy is a well-established biomarker predicting treatment outcomes, while no genomic biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ETS Translocation Variant 6 Protein

Share to Genomics

Share to Oncogene Proteins, Fusion

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to Proto-Oncogene Proteins c-ets

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 40634509
DOI: 10.1038/s41375-025-02683-7
PMCID: PMC12380598

Genes

ETV6
RUNX1
FKBP4
IGK
INTS1
KRAS
NF1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic determinants of therapy response in ETV6::RUNX1 leukemia.PMID 40634509Read ↗

The Clinical and Genetic Features of ETV6/RUNX1-like Acute Lymphoblastic Leukemia in Pediatric: A Multicenter Retrospective StudySemantic proximity Read ↗

ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosisSemantic proximity Read ↗

Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.Semantic proximity Read ↗

Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

The correlation pattern of acquired copy number changes in 164 ETV6/RUNX1-positive childhood acute lymphoblastic leukemias.Semantic proximity Read ↗

ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.Semantic proximity Read ↗

RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.Semantic proximity Read ↗

Integrated Genomic Profiling of Pediatric Acute Lymphoblastic Leukemia: Genomic Landscape, Risk Stratification and Association of RAS Pathway Mutations with Early Treatment Response.Semantic proximity Read ↗

Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemiaSemantic proximity Read ↗

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signalingSemantic proximity Read ↗

Genome-wide analysis of cytogenetic aberrations in ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia.Semantic proximity Read ↗

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.